Columvi (Glofitamab-gxbm)

Columvi (glofitamab-gxbm) is a bispecific CD20-directed CD3 T-cell engager used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has returned back (relapsed) or that did not respond to earlier treatment (refractory), and who have received a couple of or more prior therapies for their disease.

Recommended Dosage: The recommended dosage of Columvi injection is administered as a drip into a vein (an intravenous infusion). Patients will be given 12 treatment cycles. Each lasts 21 days. A doctor will begin treatment with a low dose of Columvi and will gradually enhance it to the full dose. A typical schedule is as follows.

Cycle 1: This will include a pre-treatment with obinutuzumab and 2 low doses of Columvi during the 21 days:

Day 1 – Pre-treatment with obinutuzumab 1,000 mg intravenously 7 days prior to starting Columvi

Day 8 – starting low dose of Columvi 2.5 mg

Day 15 – the second low dose of Columvi  10 mg

Cycle 2 to Cycle 12: During 2-12 cycles, patients will only be given one dose of Columvi every 21 days:

Day 1 – full dose of Columvi 30 mg

The first infusion will be given over four hours. A doctor will monitor patients carefully during the first infusion and for 10 hours after the infusion. This is to look out for any signs or symptoms of CRS.

Continue treatment for a maximum of 12 cycles (inclusive of Cycle 1 step-up dosing) or until disease progression or unacceptable toxicity, whichever occurs first.

• • Columvi 2.5 mg or 10 mg can cause severe and fatal cytokine release syndrome (CRS). Administer this medicine in a facility equipped to manage and monitor CRS. Start therapy as per the Columvi step-up dosing schedule to minimize the probability of CRS, administer pretreatment medicines, and ensure sufficient hydration.
  • Columvi can cause severe and fatal neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity (ICANS). Evaluate patients for signs and symptoms of neurologic toxicity, monitor, and provide supportive therapy; withhold or permanently discontinue this treatment based on severity.
  • Columvi can cause severe or fatal infections. Do not administer it in those patients with an active infection. Antimicrobial prophylaxis needs to be administered as per guidelines. Monitor patients prior to and throughout treatment for infection and treat accordingly. 
  • Glofitamab 2.5 mg or 10 mg can cause critical tumor flare. Those with bulky tumors or diseases situated in near proximity to airways or a vital organ should be evaluated closely during initial therapy. Assess for signs and symptoms of compression or obstruction because of mass effect secondary to tumor flare, and institute suitable treatment.
  • The mechanism of action suggests that Columvi may cause fetal harm if administered to a pregnant woman. Females of reproductive potential should use effective contraception during treatment with Columvi injection and for 30 days after the final dose.

What documents are required to import COLUMVI to India?

COLUMVI (glofitamab-gxbm) injection can be imported by patients or government hospitals on behalf of patients.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patient’s diagnostic reports.
• Patient’s ID proof (issued by the Government of India).

How is the order confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from a doctor.
• Import permit if applicable.

Is COLUMVI available in India?

COLUMVI (glofitamab-gxbm injection) is a prescription pharmaceutical drug that legally requires a medical prescription to be dispensed. Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability of Columvi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.).
• Medicine Price.
• Finding genuine and reliable sources from the USA, Canada, Europe, and Australia.
• Ensuring 100% transparency.

COLUMVI can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and, if required, an import permit.

Urgent Meds can facilitate the supply of COLUMVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for Columvi price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is able to source COLUMVI (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Columvi®?

Glofitamab-gxbm is the Generic Name for the trade name drug Columvi®.

What is the Manufacturer’s Name of Columvi®?

Columvi® is manufactured by Genentech, Inc.

Is Columvi® approved by the FDA?

Yes, Columvi® is approved by the FDA. Date of approval: June 15, 2023.

Where can I get Columvi® at the best price in India?

To get the best Columvi® injection price in India, kindly connect with Urgent Meds (a WHO GDP & ISO 9001:2008 certified company). For Columvi®, a valid medical prescription is required from a treating physician.

What is the dosage and form of Columvi® supplied?

Columvi® is supplied as Injections: 2.5 mg/2.5 mL (1 mg/mL) & 10 mg/10 mL (1 mg/mL) in a single-dose vial for intravenous use/administration.

What are the most common side effects of Columvi®?

The most common side effects of Columvi® are CRS, rash, muscle and bone pain, and tiredness.

How much does Columvi® cost in India?

The cost of Columvi® in India can vary. In order to procure this medicine legally, you can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in.

What are the storage conditions of Columvi®?

Store refrigerated at 2-8°C (36-46°F) in the original carton to protect from light. Do not freeze. Do not shake the vials.

Is it safe to buy Columvi® online in India?

Yes, one can buy Columvi® online in India at the lowest price from Urgent Meds if the medicine Columvi® is not (yet) registered or available in your country. We can help facilitate the supply of Columvi® through legal channels.